These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 21897052)

  • 1. Bridging from preclinical to clinical studies for tyrosine kinase inhibitors based on pharmacokinetics/pharmacodynamics and toxicokinetics/toxicodynamics.
    Hoshino-Yoshino A; Kato M; Nakano K; Ishigai M; Kudo T; Ito K
    Drug Metab Pharmacokinet; 2011; 26(6):612-20. PubMed ID: 21897052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
    Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process.
    Choo EF; Alicke B; Boggs J; Dinkel V; Gould S; Grina J; West K; Menghrajani K; Ran Y; Rudolph J; Wenglowsky S
    Xenobiotica; 2011 Dec; 41(12):1076-87. PubMed ID: 21864203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor.
    Liu L; Halladay JS; Shin Y; Wong S; Coraggio M; La H; Baumgardner M; Le H; Gopaul S; Boggs J; Kuebler P; Davis JC; Liao XC; Lubach JW; Deese A; Sowell CG; Currie KS; Young WB; Khojasteh SC; Hop CE; Wong H
    Drug Metab Dispos; 2011 Oct; 39(10):1840-9. PubMed ID: 21742900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.
    Nelson MH; Dolder CR
    Ann Pharmacother; 2006 Feb; 40(2):261-9. PubMed ID: 16418322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
    Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome.
    Yang B; Papoian T
    J Appl Toxicol; 2012 Dec; 32(12):945-51. PubMed ID: 22961481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of RO5068760, an MEK inhibitor, in healthy volunteers: assessment of target suppression.
    Lee L; Niu H; Goelzer P; Rueger R; Deutsch J; Busse-Reid R; DeSchepper S; Blotner S; Barrett J; Weissgerber G; Peck R
    J Clin Pharmacol; 2010 Dec; 50(12):1397-405. PubMed ID: 20386016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotoxicity induced by tyrosine kinase inhibitors.
    Orphanos GS; Ioannidis GN; Ardavanis AG
    Acta Oncol; 2009; 48(7):964-70. PubMed ID: 19734999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P; Könen-Bergmann M; Schepers C; Haertter S
    Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity-based kinase profiling of approved tyrosine kinase inhibitors.
    Kitagawa D; Yokota K; Gouda M; Narumi Y; Ohmoto H; Nishiwaki E; Akita K; Kirii Y
    Genes Cells; 2013 Feb; 18(2):110-22. PubMed ID: 23279183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L; Pang J; Plise EG; Chou B; Halladay JS; Olivero AG; Rudewicz PJ; Tian Q; Wong S; Zhang X
    Xenobiotica; 2011 Dec; 41(12):1088-99. PubMed ID: 21838594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase.
    Uckun FM; Zheng Y; Cetkovic-Cvrlje M; Vassilev A; Lisowski E; Waurzyniak B; Chen H; Carpenter R; Chen CL
    Clin Cancer Res; 2002 May; 8(5):1224-33. PubMed ID: 12006542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Species differences in distribution and prediction of human V(ss) from preclinical data.
    Berry LM; Li C; Zhao Z
    Drug Metab Dispos; 2011 Nov; 39(11):2103-16. PubMed ID: 21852367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of the tyrosine kinase EphB4. Part 3: identification of non-benzodioxole-based kinase inhibitors.
    Bardelle C; Barlaam B; Brooks N; Coleman T; Cross D; Ducray R; Green I; Brempt CL; Olivier A; Read J
    Bioorg Med Chem Lett; 2010 Nov; 20(21):6242-5. PubMed ID: 20850301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
    Tan SY; Kan E; Lim WY; Chay G; Law JH; Soo GW; Bukhari NI; Segarra I
    J Pharm Pharmacol; 2011 Jul; 63(7):918-25. PubMed ID: 21635257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
    Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
    Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
    Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.